MSB 7.69% $1.19 mesoblast limited

Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-15

  1. 2,019 Posts.
    lightbulb Created with Sketch. 315
    I smile and stamp my feet.
    I want the readouts for CHF and CLBP clinical's due mid 2020.
    While I applaud the company for giving us a next step news item, its all part of the process right?
    Anyways another feather in the bow, box ticked, curve in the road.
    Remember 4c due 31st....
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.